Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive Transfer of gp100-Reactive Lymphocytes and rF-gp100P209 Vaccine in Metastatic Melanoma
NCT00080353Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- Dec 2007
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gp100:154-162 reactive peripheral blood lymphocytes, rF-gp100P209 in melanoma, sponsored by National Cancer Institute. Started Mar 2004; status: completed.
02
Drugs
gp100:154-162 reactive peripheral blood lymphocytesrF-gp100P209
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00080353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080353.